OA02.1. Radiation-Induced Lymphopenia During Neoadjuvant Chemoradiotherapy as Predictive Biomarker for Nivolumab Benefit in Esophageal Cancer
Diseases of the Esophagus · 22.08.2026 · 39 (Supplement_1)
DOI: 10.1093/dote/doag077.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diseases of the Esophagus, online erschienen am 22.08.2026. Verfasst von Pim Damen und 21 weiteren Autor:innen.
Abstract (Originalsprache)
Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Radiation-induced lymphopenia (RIL) is an established prognostic factor associated with poorer pathologic response, disease-free survival (DFS), and overall survival (OS) in locally advanced esophageal cancer patients undergoing concurrent chemoradiotherapy (CRT). In resectable patients, standard treatment can consist of neoadjuvant CRT followed by surgery, with adjuvant nivolumab indicated (since 2022) for incomplete pathologic response. As immunotherapy efficacy relies on lymphocyte function, we hypothesize that RIL may attenuate nivolumab benefit. This study evaluates whether RIL during neoadjuvant CRT predicts nivolumab efficacy in esophageal cancer.
Methods
In this multicenter retrospective cohort study (2020–2024), patients from six hospitals with esophageal cancer showing incomplete pathologic response after neoadjuvant CRT and esophagectomy and available absolute lymphocyte counts (ALCs) at baseline and during CRT, were analyzed. To avoid immortal time bias, only patients surviving ≥90 days post-surgery were included. Severe RIL was predefined as grade ≥3 lymphopenia (ALC <0.5K/μL) in week 3 of CRT; the threshold best distinguishing survival in the largest series to date. Baseline characteristics were compared between groups with versus without severe RIL, and subsequent survival analyses for patients with nivolumab versus without nivolumab were analyzed within each group. DFS and OS were calculated from esophagectomy using Kaplan-Meier analyses, and compared between nivolumab and no nivolumab using Cox regression analyses. Baseline differences between nivolumab and no nivolumab groups were primarily driven by diagnosis year (i.e. reimbursement), but residual imbalances were adjusted via inverse-probability-of-treatment-weighting (IPTW).
Results
Among 264 patients, those with severe RIL (n=117 [44%]) had significantly higher cN- and overall clinical stage, and lower baseline ALC. In the 147 patients without severe RIL, significantly better outcomes were observed with nivolumab (n=63; DFS: hazard ratio [HR] 0.43, 95% confidence interval [CI] 0.20-0.90; OS: HR 0.20, 95%CI 0.08-0.53; Figure 1), even after IPTW-adjustment (DFS: HR 0.44, 95%CI 0.19-1.01; OS: HR 0.19, 95%CI 0.07-0.54). In the 117 patients with severe RIL, no significant outcome advantages were observed with nivolumab (n=55; DFS: HR 0.92, 95%CI 0.47-1.82; OS: HR 0.67, 95%CI 0.34-1.32; Figure 2), also not after IPTW-adjustment (DFS: HR 0.64, 95%CI 0.41-1.74; OS: HR 0.56, 95%CI 0.27-1.15).
Conclusion
Patients with severe RIL during neoadjuvant CRT do not seem to benefit from adjuvant nivolumab for esophageal cancer. The DFS and OS benefit of adjuvant nivolumab appears confined to patients without severe RIL. How this relates to PD-L1-status is under investigation. This hypothesis-generating study indicates RIL might serve as predictive biomarker for nivolumab benefit in esophageal cancer.
Zitieren
APA
Damen, P., Ozden, G., Berbée, M., Haan, J. D., Derks, S., Mohammad, N. H., Korevaar, E., Laarhoven, H. V., Leede, M. D., Mohan, R., Mostert, B., Mook, S., Nout, R., Stam, B., Schneiders, F., Tomassen, M., Verhoeff, J., Verhoeven, R., Warmerdam, F., …, & Rossum, P. V. (2026). OA02.1. Radiation-Induced Lymphopenia During Neoadjuvant Chemoradiotherapy as Predictive Biomarker for Nivolumab Benefit in Esophageal Cancer. Diseases of the Esophagus, 39(Supplement_1). https://doi.org/10.1093/dote/doag077.013
Vancouver
Damen P, Ozden G, Berbée M, Haan JD, Derks S, Mohammad NH, et al. OA02.1. Radiation-Induced Lymphopenia During Neoadjuvant Chemoradiotherapy as Predictive Biomarker for Nivolumab Benefit in Esophageal Cancer. Diseases of the Esophagus. 2026;39(Supplement_1). doi:10.1093/dote/doag077.013
BibTeX
@article{Damen2026,
author = {Damen, Pim and Ozden, Gulsah and Berbée, Maaike and Haan, Jacco de and Derks, Sarah and Mohammad, Nadia Haj and Korevaar, Erik and Laarhoven, Hanneke van and Leede, Marlinde de and Mohan, Radhe and Mostert, Bianca and Mook, Stella and Nout, Remi and Stam, Barbara and Schneiders, Famke and Tomassen, Mathijs and Verhoeff, Joost and Verhoeven, Rob and Warmerdam, Fabienne and Muijs, Christina and Lin, Steven and Rossum, Peter van},
title = {OA02.1. Radiation-Induced Lymphopenia During Neoadjuvant Chemoradiotherapy as Predictive Biomarker for Nivolumab Benefit in Esophageal Cancer},
journal = {Diseases of the Esophagus},
year = {2026},
volume = {39},
number = {Supplement_1},
doi = {10.1093/dote/doag077.013}
}
EUVIMED